banner
October 2017
David Craig, PharmD | Editor

Funding Announcements

NIH Development of a Device to Objectively Measure Pain (R43/R44)

The National Institutes of Health (NIH) encourages Small Business Innovation Research into the development of a technology/device that objectively indicates the presence and level of pain. Many of the recent advances in the development of pain measures have been made because of new and improved technologies. Because of these developments, NIH believes it is feasible to develop clinical tools to measure biomarkers or surrogate markers for the presence of acute or chronic pain. Tools like this would improve clinical pain research and treatment and provide more personalized treatment options for people in pain that do not rely on opioids.

United States small business concerns (SBCs) are eligible to apply for this grant. SBCs may submit applications as early as November 5, 2017, and must submit applications no later than 5 pm in their local time zone on December 5, 2017.

Learn More


NIH Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R01, R03, R21)

The purpose of this funding opportunity announcement (FOA) is to (1) promote preclinical, translational, clinical, and epidemiological research on pain medication use in children or pregnant women to fill knowledge gaps in the safe use of the pain medications in these special populations; and (2) develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments.

There is a need for data on pain medications used in children and pregnant women to be shared and made available to the scientific community for future studies and to encourage replication of findings and meeting the goal of further advancing research in this area.

Applications can be submitted as early as September 25, 2017, and no later than January 8, 2018. Eligibility criteria and more information can be found on the NIH website.

Learn More


NIH Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01)

The NIH aims to fund research designed to assess the clinical value of adjuncts prescribed to chronic pain patients together with opioid analgesics. Adjuncts of interest are either approved by the FDA or have previously been studied as an Investigational New Drug. Studies with adjuncts of interest should be focused on enhancing analgesia, rather than on reducing an adverse effect. A secondary purpose is to increase awareness among opioid prescribers of the potential value of adjunctive therapies by focused data dissemination.

It is hoped that increasing the availability of data describing the use of opioid adjuncts will increase their use and diminish the levels of opioids needed for analgesia. Reductions in the dosage of opioids prescribed would improve the quality of life of chronic pain patients by reducing opioid-associated adverse effects and lowering the risk of addiction development.

Applications can be submitted as early as September 25, 2017, and no later than January 8, 2018. Eligibility criteria and more information can be found on the NIH website.

Learn More